# gMG FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/gmg

> No upcoming FDA catalysts in gMG; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for gMG?

No upcoming FDA catalysts in gMG; 2 past events are recorded. Press release filed with the SEC (EX-99): "•Vertex expects to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG in the first half of 2026." [Calendar and source filings](https://sec-api.dev/indications/gmg)

Source: Press release filed with the SEC (EX-99), accession 0000875320-26-000034, https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm (retrieved 2026-11-12). Last confirmed 2026-02-13. Cite: https://sec-api.dev/indications/gmg#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 22, 2022 | [VYVGART (efgartigimod) topline data readout](https://sec-api.dev/pdufa/efgartigimod) | ARGX | gMG | completed, met | "On March 22, 2022, we announced positive topline results from the Phase 3 ADAPT-SC clinical trial, a registrational non-inferiority bridging clinical trial of efgartigimod SC for the treatment of gMG. efgartigimod SC achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to VYVGART IV formulation in gMG patients." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000169786225000020/argenx-integratedannualr.htm)) |
| 1H 2026 | [Povetacicept trial start](https://sec-api.dev/pdufa/povetacicept) | VRTX | gMG | scheduled | "•Vertex expects to initiate a placebo-controlled, Phase 2 dose-ranging proof-of-concept study evaluating povetacicept for the treatment of gMG in the first half of 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/875320/000087532026000034/ex-991_q42025.htm)) |

## Drugs

- [VYVGART (efgartigimod)](https://sec-api.dev/pdufa/efgartigimod) (ARGX)
- [Povetacicept](https://sec-api.dev/pdufa/povetacicept) (VRTX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/gmg.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "gMG FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/gmg

```bibtex
@misc{secapidev_indications_gmg_20261116,
  title        = {gMG FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/gmg}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_gmg_20261116","title":"gMG FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/gmg","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
